CN107530275A - 用于离子电渗的粘性聚合物基质和包括该基质的用于离子电渗的装置 - Google Patents
用于离子电渗的粘性聚合物基质和包括该基质的用于离子电渗的装置 Download PDFInfo
- Publication number
- CN107530275A CN107530275A CN201680017338.5A CN201680017338A CN107530275A CN 107530275 A CN107530275 A CN 107530275A CN 201680017338 A CN201680017338 A CN 201680017338A CN 107530275 A CN107530275 A CN 107530275A
- Authority
- CN
- China
- Prior art keywords
- matrix
- region
- electrode
- conductive region
- electric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 73
- 239000002998 adhesive polymer Substances 0.000 title claims abstract description 12
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 2
- 239000011149 active material Substances 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 208000012659 Joint disease Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000005392 Spasm Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 208000025747 Rheumatic disease Diseases 0.000 description 5
- 208000006111 contracture Diseases 0.000 description 5
- 230000005611 electricity Effects 0.000 description 5
- 229960004264 idrocilamide Drugs 0.000 description 5
- 108010032809 mucopolysaccharidase Proteins 0.000 description 5
- 230000000552 rheumatic effect Effects 0.000 description 5
- 230000003637 steroidlike Effects 0.000 description 5
- 206010062575 Muscle contracture Diseases 0.000 description 4
- 208000000491 Tendinopathy Diseases 0.000 description 4
- 206010043255 Tendonitis Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000003356 anti-rheumatic effect Effects 0.000 description 4
- 239000003435 antirheumatic agent Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000020764 fibrinolysis Effects 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 201000004415 tendinitis Diseases 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000036487 Arthropathies Diseases 0.000 description 3
- 208000035484 Cellulite Diseases 0.000 description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010049752 Peau d'orange Diseases 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 201000008907 algoneurodystrophy Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- 230000036232 cellulite Effects 0.000 description 3
- 230000002615 fibrolytic effect Effects 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000003836 peripheral circulation Effects 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- OSCTXCOERRNGLW-UHFFFAOYSA-N Idrocilamide Natural products OCCNC(=O)C=CC1=CC=CC=C1 OSCTXCOERRNGLW-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000019804 backache Diseases 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- OSCTXCOERRNGLW-VOTSOKGWSA-N idrocilamide Chemical compound OCCNC(=O)\C=C\C1=CC=CC=C1 OSCTXCOERRNGLW-VOTSOKGWSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920000307 polymer substrate Polymers 0.000 description 2
- -1 polysiloxanes Polymers 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XXQMDKCWUYZXOF-UHFFFAOYSA-N 3-(2-chlorophenothiazin-10-yl)propyl-diethylazanium;chloride Chemical compound Cl.C1=C(Cl)C=C2N(CCCN(CC)CC)C3=CC=CC=C3SC2=C1 XXQMDKCWUYZXOF-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000553739 Aconitum carmichaelii var. truppelianum Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- KVPMCFRZLDLEJW-UHFFFAOYSA-N C(C(=O)O)(=O)O.NCCC(=O)O Chemical compound C(C(=O)O)(=O)O.NCCC(=O)O KVPMCFRZLDLEJW-UHFFFAOYSA-N 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010049949 Intercostal neuralgia Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 206010057267 Periphlebitis Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- RHTNTTODYGNRSP-UHFFFAOYSA-N Tolazoline hydrochloride Chemical compound Cl.C=1C=CC=CC=1CC1=NCCN1 RHTNTTODYGNRSP-UHFFFAOYSA-N 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Inorganic materials [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 201000005547 chronic conjunctivitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Natural products O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Natural products NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 210000000835 hypertrophic cicatrix Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229950004597 prednisolone succinate Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 229920006268 silicone film Polymers 0.000 description 1
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver nitrate Substances [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 201000008417 spastic hemiplegia Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960002040 tiratricol Drugs 0.000 description 1
- 229960002649 tolazoline hydrochloride Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0492—Patch electrodes
- A61N1/0496—Patch electrodes characterised by using specific chemical compositions, e.g. hydrogel compositions, adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
Abstract
本发明涉及一种用于通过离子电渗递送活性成分的粘性聚合物基质(1),其具有用于施加到皮肤上的第一面(7)和用于与电极配合的第二面(8),其特征在于,该粘性聚合物基质包括多个导电区域(2)和至少一个电绝缘区域(3),每个所述导电区域(2)通过电绝缘区域(3)与另一导电区域(2)绝缘。本发明涉及使用电流以促进活性物质经皮扩散的技术,更具体地,涉及离子电渗装置。
Description
技术领域
本发明涉及用于离子电渗的粘性聚合物基质和包括所述基质的用于离子电渗的装置。
本发明涉及使用电流以促进活性物质经皮扩散的技术,更具体地涉及用于离子电渗疗法的装置。
背景技术
离子电渗是一种可用于化妆品和/或医疗用途的技术,目的是通过电流将活性物质引入皮肤真皮。
离子电渗装置包括含有待施用的含有活性物质的槽或贴片。这些槽或贴片应用在设备和用户皮肤之间。这些装置的目的是通过电流将活性物质从槽或贴片运送到真皮。电流必须通过真皮在电极之间循环。然而,采用目前的设备,实际上很少的电流通过真皮循环。致使活性物质的施用量减少。
因此,需要提出一种解决方案,以对活性物质至真皮的运送进行改进。
发明内容
为了达到这个目的,本发明涉及一种用于离子电渗的粘性聚合物基质,其具有被配置为用于施加到皮肤上的第一面和被配置为与电极配合的第二相对面。该基质包括多个导电区域和至少一个电绝缘区域,每个所述导电区域通过电绝缘区域与另一导电区域电绝缘。
这样的基质确保电流最佳地通过真皮。实际上,具有相反极性的两个电极之间的电流循环只能通过真皮,在通过基质的两个导电区域之间不存在导电通路。因此,根据本发明的基质可以消除任何对离子电渗效率产生负面影响的泄漏电流。电流通过皮肤在两个导电区域之间循环,从而携带至少一种待施用的活性成分。
根据另一方面,本发明涉及一种电渗疗法装置,该电渗疗法装置包括电极和能量源,以及如上所述的基质。
附图说明
附图作为实例给出,并不限制于本发明。它们是用于促进对本发明的理解的原理性示意图,并不一定是实际应用的尺寸。
图1示出了根据本发明的基质的导电和电绝缘区域的配置的一个示例的俯视图。
图2示出了根据本发明的装置应用于皮肤上的横截面视图。
图3示出了根据本发明的基质的导电和电绝缘区域的配置的另一个示例的俯视图。
附图标记说明
1 基质
2 导电区域
3 绝缘区域
4 皮肤
5A,5B 电极
6 能量源
7 第一面
8 第二面
具体实施方式
在对本发明的实施方式进行详细评述之前,以下将列出可选特征,可选地,它们可以一起或者替代地使用。
首先,要强调的是,本发明涉及一种递送用于离子电渗的活性成分的粘性聚合物基质,其具有用于施加到皮肤上的第一面和用于与电极配合的第二面,其特征在于,该粘性聚合物基质包括多个导电区域和至少一个电绝缘区域,每个所述导电区域通过电绝缘区域与另一导电区域绝缘。
有利的是,根据本发明的基质,所述多个导电区域含有至少一种待递送的活性成分。
有利的是,所述多个导电区域被配置为与能够提供电流的电极配合,每个导电区域的至少一种活性成分根据与所述区域配合的电极的极性得以选择。
有利的是,所述多个导电区域含有不同的活性成分。
有利的是,所述至少一个电绝缘区域将两个导电区域分隔开的最小宽度为1mm。
有利的是,所述区域在基质的整体厚度上延伸。
有利的是,所述基质含有至少一种聚合物、至少一种胶粘剂和至少一种增塑剂;
有利的是,所述基质含有吸收促进剂。
本发明还涉及一种用于离子电渗的装置,该装置包括至少两个电极和与电极电连接的能量源,其特征在于,该装置包括粘性聚合物基质。有利的是,粘性聚合物基质的导电区域与电极连接。
本发明涉及用于离子电渗的粘性聚合物基质。所述基质1包括第一面7和相对的第二面8。所述第一面7用于被施加到使用者的皮肤上,有利地位于待处理的区域。所述第二面8被设置为与离子电渗装置配合,更具体地是与电极5a,5b配合。
所述离子电渗装置包括电极5a,5b和能量源6。该装置可以是各种形式的,不论是仅电连接到远程能量源的电极,或是例如申请人的在前专利申请中描述的盒体或贴片的形式。有利地,该装置包括电子模块,该电子模块有利地是激活装置,例如控制按钮。有利地,电子模块包括控制装置和生理参数的测量装置,例如温度、pH、压力、相对湿度、电阻率的测量装置。
有利的是,所述电子模块用于控制提供给电极5a,5b的电流。有利地,所述电子模块能够控制强度、电压和/或施用时间。根据一种可能性,所述电子模块包括微处理器。
根据一种可能性,所述能量源6是一种电源,例如是可再充电的蓄电池或电池,其能够例如经过电压发生器将电压施加到电极5a,5b。所述能量源6可以具有变型。有利地,所述能量源6是独立的,例如可以是回收能量的独立能量发生器或可用的电池。
根据有利的实施方式,所述电子模块包括能量源,优选地是独立的电流源。这种配置对于根据本发明的装置的动态使用是特别有利的。
该装置有利地配置为能够传递具有受控强度的电流。优选地,强度I小于或等于1mA。
所述电极5a,5b允许电流通过所述基质1有利地沿着其厚度方向,更具体地是沿着下面将描述的所述导电区域2传递到所述皮肤4。
本发明的所述装置有利地包括升压变压器。所述升压变压器有利地存在于所述电子模块中。所述升压变压器能够将从所述能量源传递的电压升高为提供给所述电极的电压。
根据优选的实施方式,所述基质1可以与所述装置分离,也就是说,可拆卸。优选地,该装置是可重复使用的。有利地,所述基质1是消耗品,其被单次或多次使用,但是比装置的使用次数少。所述基质是一次性的。这是从生态和经济角度出发的,因为该装置包括电极5a、5b。
根据本发明的所述装置提供了一种既可以是一次性使用的装置,也可以至少用于单个患者,同时重新使用昂贵的电子元件。
根据本发明,所述基质1为柔性布料。其灵活性使得基质轮廓的两个相对点可以连接在一起而不损坏所述基质1。当所述装置连接到所述基质1上并被固定时,能够有利地保持这种灵活性。
优选地,所述基质1的厚度为25~60μm。基质的灵活性使得所述基质与要被施用的身体部位相适应。
根据本发明的所述装置和所述基质1可以容易地使用在人体的所有部位上,并且对于使用者来说并无困难或不适。
所述基质1至少含有用于施用到使用者的皮肤4的活性成分。活性成分是指对使用者具有治疗或美容作用的物质。
根据本发明的基质1包括多个导电区域2和至少一个电绝缘区域3。因此,所述多个导电区域2通过至少一个电绝缘区域3彼此绝缘。有利地,所述多个导电区域2与离子电渗装置的电极5a,5b相配合。
所述多个导电区域2被配置为使得所述装置的所述电极5a、5b和施加了所述基质1的所述皮肤之间电导通。电流从所述第二面8沿着所述基质1的厚度方向到所述第一面7从而通过所述基质1。
所述绝缘区域3被配置为使得导电体之间绝缘,特别是在所述多个导电区域2之间。
例如,在所述基质1的导电区域2中存在电离的活性成分使得所述区域上具有导电性。相反,在所述绝缘区域3中不存在电离的活性成分,优选不存在任何其它电离成分,使得所述区域具有抗导电性。
根据下述的所述基质1的制造方法,所述基质1包括膜,例如硅酮,以形成所述基质1的基体。该膜嵌入所述聚合物基质的所述聚合物中。
所述多个导电区域2和绝缘区域3形成在所述基质1的整个厚度上。
优选地,所述多个导电区域2含有至少一种活性成分。优选地,所述电绝缘区域1不含有任何活性成分。
根据优选的可能性,根据与所述区域配合的所述电极5a、5b的极性来选择每个所述导电区域2的所述活性成分。
有利地,选择所述电极以使至少一个电极具有与至少另一个电极极性相反的极性,优选地具有两个相反极性的电极,以允许电流从一个导电区域2循环通过皮肤到另一个导电区域2。
电绝缘区域3将至少两个导电区域2分隔开的最小宽度为1mm,以提供满意的绝缘性。
根据一种实施方式,所述基质1包括由至少一个电绝缘区域3分隔的多个导电区域2a、2b、2c、2d...。每个导电区域包括根据配合电极5的极性选择的不同的活性成分。根据一种可能性,所述基质1被配置为允许按顺序地离子电渗。这意味着每个导电区域2的活性成分能被依次施用。该装置被配置为依次通过电极5向导电区域2提供电流,能够使得活性成分被一个接一个地施用从而改善治疗。
每个导电区域2a、2b、2c和2d分别与至少一个电极5a、5b连接。
例如,在被配置为与阴极电极5a配合的导电区域2中,活性成分从下列的列表中选择,其中示出了可以使用这些活性成分的相对的疾病、症状或适应症的示例:
-青霉素
-磺胺10%:疖
-烟酸
-碘化钾1~3%:抗硬化,血管紧张,抗关节炎,神经紧张,纤维蛋白溶解(fibrolytic),交感神经系统紧张,血管紧张,肥大性瘢痕,动脉硬化,关节病,关节炎,无挛缩偏瘫的后遗症,周围神经损伤
-碘化钠1~3%:硬化性粘附瘢痕,瘢痕瘤,关节僵硬,杜普征氏掌挛缩
-水杨酸钠1~3%:抗风湿,止痛,抗水肿,关节炎,PSH,神经痛,静脉周围炎
-升华硫
-透明质酸酶150U 1小瓶:扩散剂,抗水肿,局部水肿,积液,淋巴管炎
-氢化可的松1%:类固醇消炎,无骨质疏松症的风湿性炎症
-泼尼松龙琥珀酸盐1%:甾体抗炎,无骨质疏松症的风湿性炎症,甾体抗炎
-倍他米松(célestène):甾体抗炎,无骨质疏松症的风湿性炎症
-倍他米松:甾体抗炎+粘多糖酶,关节病,慢性关节疾病,腱炎,关节疾病,杜普征氏掌挛缩和佩罗尼氏病,腮腺炎,腱炎
-通皮质激素(percutalgine):甾体抗炎,无骨质疏松症的风湿性炎症,关节炎,关节病
-酮洛芬:非甾体抗炎药
-酪洛芬(profénid)50与粘多糖酶:关节病,旁关节疾病
-双氯芬酸7:非甾体抗炎药
-扶他林与粘多糖酶:关节疾病
-保泰松:非甾体抗炎药
-丁唑烷:风湿性炎症,创伤后炎症
-水杨酸锂1%:抗尿酸,痛风和副疼痛疾病
-粘多糖酶:扩散剂,脂肪团,水肿,血肿,抗炎产品渗透的基础
-羟乙桂胺:肌肉松弛剂
-施力柔(srilane):抗炎
-羟乙桂胺(brolitène):肌肉挛缩,疼痛,腱炎
-硫粘多糖酶:抗水溶性,溶解性,淋巴水肿,脂肪团
-烟胺乙酯:抗炎,血管扩张剂,痛觉神经营养不良,外周循环
-尼克莫他啶(nicometat 2 amp):抗炎,痛觉神经营养不良
-阿尔莫粘蛋白酶(almomucase):抗水肿(oatematous),痛觉神经营养不良
-氯化钙:纤维蛋白溶解(fibrolytic),疤痕
-氯化钠:纤维蛋白溶解(fibrolytic),疤痕
-三碘甲腺乙酸(thriodothryacétique acid):脂肪分解,脂肪团
例如,在配置为与阳极电极5b配合的导电区域2中,活性成分如下:
-卡巴因5%:局部麻醉,痛觉过敏
-氯丙嗪:松弛肌肉
-盐酸氯丙乙(neuriplège):挛缩,痉挛,肌肉痛
-特坦尼尔(tétanil):松弛肌肉,痉挛症
-消化胰蛋白酶(alphachymotrypsine):扩散剂,抗水肿,挫伤,扭伤,oedemas
-α皮肤(alphacutanée):扩散剂,抗耳聋,挫伤,水肿(oedemas)
-冻干甲状腺:脂肪分解,脂质分解代谢,肥胖
-三碘硫代乙酸:脂肪分解,肥胖
-因弗兰尼(Inflanil):抗风湿,关节炎,腱炎,关节疾病
-有机硅:结缔组织的再生器,妊娠纹,局部脂肪团
-水杨酸锂:抗风湿,小关节炎
-肾上腺素:血管收缩剂,外周循环
-乌头碱硝酸盐:抗神经痛,止痛,三叉神经痛,带状疱疹后神经痛
-通皮质激素(percutalgine):止痛,背痛,韧带痛,腱痛
-蜂螫毒(apisin),阿皮克(apicure)(蜂毒):肋间神经痛
-硝酸银:关节性抗风湿
-乙酰胆碱0.5%
-维生素B
-氯化钙:镇静,再钙化,痛觉过敏,痉挛性偏瘫,骨质疏松症,痉挛性痉挛,痛性神经营养不良,关节僵硬
-氯化锌:防腐,慢性结膜炎,妇科,耳鼻喉科
-硫酸锌:妇科,耳鼻喉科
-氯化镁:镇静,解痉,痉挛症,平面疣
-硫酸镁:痉挛症,平面疣
-氯化铵:纤维蛋白溶解,关节僵硬
-亚麻提取物(flaxedyl):合成箭毒样药物,松弛肌肉,挛缩,斜颈,背痛,腰痛,风湿性肌挛缩,痉挛性痉挛
-多拉唑(doryl)0.1%
-组胺盐酸盐:诱导剂,痛觉过敏,坐骨神经痛
-组胺二盐酸盐:诱导剂,血管扩张剂,关节疾病
-肾上腺素磷酸盐:血管收缩剂,哮喘,外周循环
-硫酸铜:防腐,杀菌,霉菌
-可卡因
-普鲁卡因
-诺瓦卡因:局部麻醉,止痛,三叉神经痛,带状疱疹
-柠檬酸钾:痉挛症,平面疣
-辛可卡因(percaine)2~5%
-盐酸甲苯咪唑啉(priscol)5~10%
-氡100000EM
-皮质类固醇1%:关节风湿病,倍他米松(célestène,betnésol),痛风
-氢化可的松1%:关节风湿病,痛风
-赫塞他松(histacone)
-青霉素
-溴
-博敖霉素(biomycine)
-布坦霉素(butazoline)
-链霉菌密素(streptomyline)
所述基质1有利地含有至少一种聚合物,所述聚合物选自具有弹性的聚氨酯,具有绝缘能力的聚硅氧烷,具有物理强度和透明度的聚(甲基丙烯酸甲酯),具有亲水性质及强度的聚乙烯醇,具有硬度、坚固性和溶胀性的聚乙烯,具有悬浮能力的聚乙烯吡咯烷酮。
优选地,所述基质1具有粘性,也就是说,其被设置为能够胶合到或临时粘附到其所施用的皮肤上。为此,所述基质1含有至少一种选自丙烯酸、聚丙烯酸酯、聚异丁烯、聚乙烯吡咯烷酮、硅酮的胶粘剂。
根据一种实施方式,所述基质1含有至少一种选自山梨糖醇、甘油、丙二醇的增塑剂。
根据一种可能性,所述基质1含有溶剂。
根据一种实施方式,所述基质1含有选自水、醇、脂肪醇如丙二醇、氨基酸、酰胺、酯、醚如PEG、萜烯、萜类化合物和精油、亚砜、脂质的吸收促进剂。
根据优选的实施方式,使用以下方法制备所述基质1。将胶粘剂溶液与聚合物溶液混合以形成混合物A。然后,将含有增塑剂和至少一种活性成分的溶液加入到混合物A中以形成混合物B。将混合物B以有利地低于200rpm的速度缓慢搅拌相当于一夜的时间。然后将混合物倒在例如硅酮膜的至少一部分上。
制备通过丝网印刷进行。重复这些步骤以分别在与例如硅酮相同的膜的一部分上形成另一个导电区域2和绝缘区域3。该组件在干燥炉中如在80℃下干燥30分钟。制得的基质1应保存在干燥器中。
根据该实施方式,其中所述基质1包括多个分别含有各种活性成分的导电区域2a、2b、2c、2d。对于每个导电区域执行上述步骤。
根据本发明的装置可用于美容或治疗。如果该装置用于离子电渗,其旨在使活性物质渗透到真皮中,例如具有脱色作用的维生素A或视黄醇,具有局部麻醉效应的利多卡因,具有再生和形成瘢痕作用的透明质酸,用于治疗痤疮的视黄酸,具有抗氧化作用的维生素C,用于治疗红斑的β-丙氨酸二乙酸等离子螯合剂,用于改善皮肤质地的乙醇酸,具有抗炎作用的地塞米松磷酸钠或任何其它类型的被电离的或呈阴离子或阳离子乳剂形式以便能够被电流携带的活性成分。
根据有利的可能性,该装置包括多个阳极和与阳极交替的多个阴极。在这种配置中,总电流被分配成多个阳极-阴极电路,使得从阳极循环到阴极的电流的密度优选小于1mA/cm2。此外,为了防止形成外部场线,即,在装置外部,装置两端的两个电极具有相同的极性,也就是说,它们是两个阳极或两个阴极。
Claims (10)
1.用于通过离子电渗递送活性成分的粘性聚合物基质(1),其具有用于施加到皮肤上的第一面(7)和用于与电极配合的第二面(8),其特征在于,该粘性聚合物基质包括多个导电区域(2)和至少一个电绝缘区域(3),每个所述导电区域(2)通过电绝缘区域(3)与另一导电区域(2)绝缘。
2.根据前述权利要求所述的基质(1),其中,所述多个导电区域(2)含有至少一种待递送的活性成分。
3.根据前述权利要求中任一项所述的基质(1),其中,所述多个导电区域(2)被配置为与能够提供电流的电极配合,每个所述导电区域(2)的至少一种活性成分根据与该区域配合的电极(5a,5b)的极性得以选择。
4.根据前述权利要求中任一项所述的基质(1),其中,所述多个导电区域(2)含有不同的活性成分。
5.根据前述权利要求中任一项所述的基质(1),其中,所述至少一个电绝缘区域(3)将两个导电区域(2)分隔开的最小宽度为1mm。
6.根据前述权利要求中任一项所述的基质(1),其中,所述区域在所述基质的整体厚度上延伸。
7.根据前述权利要求中任一项所述的基质(1),所述基质含有至少一种聚合物、至少一种胶粘剂和至少一种增塑剂。
8.根据前述权利要求所述的基质(1),所述基质含有吸收促进剂。
9.一种用于离子电渗的装置,该装置包括至少两个电极(5a,5b)和与所述电极(5a,5b)电连接的能量源(6),其特征在于,所述装置包括根据前述权利要求中任一项所述的粘性聚合物基质(1)。
10.根据前述权利要求所述的装置,其中,所述粘性聚合物基质(1)的多个导电区域(2)与所述电极(5a,5b)连接。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1552414A FR3034017B1 (fr) | 2015-03-24 | 2015-03-24 | Matrice polymerique adhesive pour iontophorese et dispositif pour l'iontophorese comprenant ladite matrice |
FR1552414 | 2015-03-24 | ||
PCT/EP2016/056336 WO2016150994A1 (fr) | 2015-03-24 | 2016-03-23 | Matrice polymérique adhésive pour iontophorèse et dispositif pour l'iontophorèse comprenant ladite matrice |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107530275A true CN107530275A (zh) | 2018-01-02 |
CN107530275B CN107530275B (zh) | 2021-07-30 |
Family
ID=53200153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680017338.5A Active CN107530275B (zh) | 2015-03-24 | 2016-03-23 | 用于离子电渗的粘性聚合物基质和包括该基质的用于离子电渗的装置 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11007138B2 (zh) |
EP (1) | EP3273941B1 (zh) |
JP (2) | JP7063621B2 (zh) |
KR (1) | KR102585678B1 (zh) |
CN (1) | CN107530275B (zh) |
ES (1) | ES2805226T3 (zh) |
FR (1) | FR3034017B1 (zh) |
WO (1) | WO2016150994A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10361349B2 (en) | 2017-09-01 | 2019-07-23 | Cree, Inc. | Light emitting diodes, components and related methods |
JP7212483B2 (ja) * | 2018-09-10 | 2023-01-25 | 株式会社 Mtg | シワ用外用剤 |
FR3136677A1 (fr) | 2022-06-17 | 2023-12-22 | Feeligreen | Procédé iontophorétique d’administration de l’acide férulique |
FR3136675A1 (fr) | 2022-06-17 | 2023-12-22 | Feeligreen | Procédé iontophorétique d’administration d’un principe actif |
FR3136676A1 (fr) | 2022-06-17 | 2023-12-22 | Feeligreen | Procédé iontophorétique d’administration de l’acide mandélique |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4731926A (en) * | 1985-02-19 | 1988-03-22 | Drug Delivery Systems Inc. | Method of manufacturing disposable and/or replenishable transdermal drug applicators |
US5162042A (en) * | 1988-07-05 | 1992-11-10 | Alza Corporation | Electrotransport transdermal system |
CN101237905A (zh) * | 2005-08-05 | 2008-08-06 | Tti优而美株式会社 | 离子电渗装置 |
CN101528300A (zh) * | 2006-09-05 | 2009-09-09 | Tti优而美株式会社 | 使用感应电源的透皮药物输送系统、装置和方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE399044A (zh) * | 1933-09-09 | |||
CH633837A5 (de) * | 1978-06-30 | 1982-12-31 | Rueti Ag Maschf | Verfahren zur herstellung von florgewebe und webmaschine zur durchfuehrung des verfahrens. |
JPH0669442B2 (ja) * | 1985-06-24 | 1994-09-07 | 積水化学工業株式会社 | 医療用導電性粘着剤およびそれを用いた医療用粘着電極 |
US5080646A (en) * | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
US4865582A (en) * | 1987-06-05 | 1989-09-12 | Drug Delivery Systems Inc. | Disposable transdermal drug applicators |
US5147296A (en) * | 1988-10-03 | 1992-09-15 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
US5084006A (en) * | 1990-03-30 | 1992-01-28 | Alza Corporation | Iontopheretic delivery device |
JP2821267B2 (ja) * | 1990-05-30 | 1998-11-05 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | イオン導入法によって薬剤を供給する装置および方法 |
US6317629B1 (en) * | 1992-06-02 | 2001-11-13 | Alza Corporation | Iontophoretic drug delivery apparatus |
JPH078466A (ja) * | 1993-06-21 | 1995-01-13 | Dainippon Printing Co Ltd | フィルム電極 |
US5503632A (en) * | 1994-04-08 | 1996-04-02 | Alza Corporation | Electrotransport device having improved cathodic electrode assembly |
JPH0852224A (ja) * | 1994-08-12 | 1996-02-27 | Hisamitsu Pharmaceut Co Inc | イオントフォレーシス用デバイス |
US5846558A (en) * | 1996-03-19 | 1998-12-08 | Minnesota Mining And Manufacturing Company | Ionically conductive adhesives prepared from zwitterionic materials and medical devices using such adhesives |
WO1998035722A1 (fr) * | 1997-02-17 | 1998-08-20 | Kowa Co., Ltd. | Dispositif pour iontophorese |
US6119036A (en) * | 1997-03-26 | 2000-09-12 | The Board Of Regents Of The University Of Oklahoma | Iontophoretic transdermal delivery device |
JP4393641B2 (ja) * | 1998-11-26 | 2010-01-06 | 久光製薬株式会社 | イオントフォレーシス用粘着ゲル組成物及びその装置 |
JP2003138240A (ja) * | 2001-10-16 | 2003-05-14 | Three M Innovative Properties Co | 生体電極用導電性接着剤組成物及びその製造方法並びに生体電極 |
US6708050B2 (en) * | 2002-03-28 | 2004-03-16 | 3M Innovative Properties Company | Wireless electrode having activatable power cell |
AU2004291040A1 (en) * | 2003-11-13 | 2005-06-02 | Alza Corporation | System and method for transdermal delivery |
US20070150008A1 (en) * | 2004-03-25 | 2007-06-28 | Koninklijke Philips Electronics, N.V. | Defibrillation electrode having drug delivery capablity |
WO2007037476A1 (ja) * | 2005-09-30 | 2007-04-05 | Tti Ellebeau, Inc. | 睡眠導入剤と興奮剤の投与量および投与時期を制御するイオントフォレーシス装置 |
JP5506583B2 (ja) | 2010-07-23 | 2014-05-28 | 富士機械製造株式会社 | 部品実装方法 |
-
2015
- 2015-03-24 FR FR1552414A patent/FR3034017B1/fr not_active Expired - Fee Related
-
2016
- 2016-03-23 WO PCT/EP2016/056336 patent/WO2016150994A1/fr active Application Filing
- 2016-03-23 ES ES16714801T patent/ES2805226T3/es active Active
- 2016-03-23 EP EP16714801.4A patent/EP3273941B1/fr active Active
- 2016-03-23 KR KR1020177030463A patent/KR102585678B1/ko active IP Right Grant
- 2016-03-23 JP JP2017549636A patent/JP7063621B2/ja active Active
- 2016-03-23 CN CN201680017338.5A patent/CN107530275B/zh active Active
- 2016-03-23 US US15/560,644 patent/US11007138B2/en active Active
-
2020
- 2020-11-24 JP JP2020194327A patent/JP2021028009A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4731926A (en) * | 1985-02-19 | 1988-03-22 | Drug Delivery Systems Inc. | Method of manufacturing disposable and/or replenishable transdermal drug applicators |
US5162042A (en) * | 1988-07-05 | 1992-11-10 | Alza Corporation | Electrotransport transdermal system |
CN101237905A (zh) * | 2005-08-05 | 2008-08-06 | Tti优而美株式会社 | 离子电渗装置 |
CN101528300A (zh) * | 2006-09-05 | 2009-09-09 | Tti优而美株式会社 | 使用感应电源的透皮药物输送系统、装置和方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2016150994A1 (fr) | 2016-09-29 |
FR3034017B1 (fr) | 2018-11-02 |
EP3273941A1 (fr) | 2018-01-31 |
CN107530275B (zh) | 2021-07-30 |
US20180092834A1 (en) | 2018-04-05 |
KR102585678B1 (ko) | 2023-10-06 |
JP7063621B2 (ja) | 2022-05-09 |
JP2018515162A (ja) | 2018-06-14 |
ES2805226T3 (es) | 2021-02-11 |
FR3034017A1 (fr) | 2016-09-30 |
EP3273941B1 (fr) | 2020-06-17 |
US11007138B2 (en) | 2021-05-18 |
KR20170131550A (ko) | 2017-11-29 |
JP2021028009A (ja) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107530275A (zh) | 用于离子电渗的粘性聚合物基质和包括该基质的用于离子电渗的装置 | |
KR102380212B1 (ko) | 자극 장치 및 이를 이용한 자극 방법 | |
US20140378555A1 (en) | Facial treatment device | |
US20100030129A1 (en) | Dermal patch | |
CN111888641B (zh) | 离子电渗透的给药装置 | |
CN204582326U (zh) | 智能鞋 | |
CN105709331A (zh) | 一种理疗医用电极 | |
JP2017505188A (ja) | 少なくとも2つのコンパートメントを含む電気マスク | |
US20130253412A1 (en) | Roller-ball applicator for transdermal iontophoretic delivery | |
US20190105486A1 (en) | Support for transdermal application of substances | |
WO2018117343A1 (ko) | 플라즈마 방전식 피부 처치 장치 | |
US10238866B2 (en) | Iontophoresis device with multi-electrode end piece | |
CN204815381U (zh) | 智能手套 | |
RU2782120C1 (ru) | Устройство для осуществления ионтофореза | |
Ibáñez et al. | MOLECULAR MECHANISMS OF INTRATISSUE PERCUTANEOUS ELECTROLYSIS (EPI® TECHNIQUE) | |
KR20090090057A (ko) | 갈바닉 이온도입 기능을 갖는 화장품용기 | |
TWI606819B (zh) | Carrying one-piece heating and low-frequency dual-function therapeutic device | |
TWM495194U (zh) | 複合式軟性離子導入加熱裝置 | |
RU2500438C2 (ru) | Способ физиотерапии | |
KR20190093404A (ko) | 플라즈마 방전을 이용한 피부 치료기 | |
KR20040028116A (ko) | 전기가 통하는 상태의 물에서 목욕방법. | |
ITGO20100004A1 (it) | Dispositivo elettro-diffusore per fisioterapia | |
Parker | Recent Applications of Electricity: III. Static Electricity | |
RU2003134374A (ru) | Способ и система электрокинетического ввода вещества | |
Teslim | DEFINITION PHYSIOTHERAPY BY CSP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |